What's Happening?
Eli Lilly and Company announced results from two late-phase trials, ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, demonstrating that patients with obesity maintained significant weight loss using Foundayo and lower-dose Zepbound after transitioning from higher
doses of injectable incretin therapy. The trials, presented at the European Congress on Obesity, showed that participants maintained nearly all of their previous weight loss over a year. Foundayo and Zepbound, both GLP-1 receptor agonists, were effective in long-term weight management, with safety profiles consistent with prior studies.
Why It's Important?
The findings are significant as they address the challenge of weight regain in obesity treatment, offering new options for long-term weight management. This could impact the obesity drug market by providing alternatives for patients who struggle with maintaining weight loss after initial treatment. The results may influence healthcare providers' decisions in prescribing weight management therapies, potentially benefiting patients with obesity-related health issues.
What's Next?
Eli Lilly plans to continue exploring the potential of these medications in various patient populations. The company is committed to providing diverse treatment options for obesity, which may lead to further clinical trials and regulatory submissions. The ongoing research could also prompt discussions on healthcare policy regarding obesity treatment coverage.
